

Beyond Validation: Getting Apps into Clinical Practice

David W. Bates, Professor of Medicine,
Harvard Medical School

Medical Director of Clinical and Quality
Analysis, MGB Healthcare

Overview

- Current U.S. status
- Regulatory backdrop
- Framework for prescribing apps
 - Education/awareness
 - Creating digital formularies
 - Workflow and EHR integration
 - Payment models
 - Patient/provider support
- Conclusions


Gordon, Landman,
Zhang, and Bates, npj Digital
2020

Regulation

- In U.S., Digital Health Action Innovation plan issued by FDA
- Two main categories: SaMD—Software as a Medical Device, and SiMD—Software in a Medical Device
- Also multiple frameworks in Europe



Education/Awareness

- Training
 - Medical school
 - Post-graduate
 - Especially important for prescription-only regulated apps like on-line CBT to support outpatient substance use disorder treatment
 - Patients can also benefit
 - But consumer ratings don't correlate with clinical utility
 - Labeling critical
- 

Creating digital formularies

- Traditional formularies relate to drugs
- But “digital formularies” could be highly beneficial for promoting the use of high-value apps
- Key purposes:
 - Short list of apps for a specific condition or purpose (with subcategories within condition)
 - Could be better from safety perspective
 - Could enable streamlined coverage and pricing like medication formularies
 - Could help patients know which apps are supported by organization and could interoperate with HER
- Two main risks:
 - Could result in worse pricing for patients
 - Could slow diffusion of new apps to patients

Mass General Brigham Example

- Have a relationship with Xhealth
 - Makes it easy for an organization to deploy multiple apps
 - Streamlines linkage with EHR
- Still early days for us
 - BabyScripts
 - Force Therapeutics—collection of PROMs data in orthopedics
 - Many types of educational materials
 - Plan is to broaden offerings
 - But is a lot of work to vet the individual apps

Workflow and EHR integration

- In U.S., average outpatient visit is 17.4 minutes
 - Many competing priorities
- For this to work well:
 - Apps should be searchable and orderable
 - Should be integrated with clinical decision support to ensure appropriateness
 - Providers should be able to note reason for use
 - Providers should be able to enter “sig” —or label for the prescription
 - Providers should be able to prescribe parameters which can be loaded
 - App should interoperate with EHR
 - Data gathered should be viewable by patient and provider
- Many will be used long-term (e.g. for a chronic condition), but others will be short-term (e.g. for a procedure like a colonoscopy)

Payment models

- Simplest is to have patients pay
 - That is almost certainly not sufficient and could promote inequities
- Reimbursement by insurance is an attractive alternative
 - Unique reimbursement challenges—e.g. how new versions are managed and paid for
- Innovations possible
 - Could allow “trial periods”
 - Accountable care organizations could choose to pay
 - Could also be packaged with other services like drugs or devices

Patient/provider support

- Patients may need support
- Especially for high-cost, high-need patients (who could benefit most)
 - In one study we did in such patients with diabetes, only 40% could even enter their glucose
 - But all patients said they wanted to use apps
- Ochsner System (in Louisiana) uses the “O Bar,” which is a physical space patients can go to get recommended digital interventions, troubleshoot issues
 - Includes mechanisms to test apps and receive digital devices like Bluetooth-enable glucose monitors

Clinical Example

- 57 YO woman presents with a hemoglobin A1c of 9.6
- Physician changes diabetic medication, but also prescribes an app which will let her track more effectively
 - Selects one which is available in Spanish and is highly rated
- Patient's data are transmitted to the practice EHR go directly to a Spanish-speaking diabetes manager who works with the primary care physician and also provides some coaching
- App is covered by her accountable care organization because it has high ratings for patients like this one
 - They realize this approach is more cost-effective than newest medications

Conclusions

- Apps are highly promising, but multiple issues must be addressed
 - Apps usually required smartphones or tablets—access is an issue, especially for older and socioeconomically disadvantaged patients
 - How apps will affect provider burnout is a concern
- New regulatory approaches as we are discussing today are critical
- Great potential for improvement but this is not yet being realized at scale